ANL 19.29 Decreased By ▼ -1.56 (-7.48%)
ASC 13.45 Decreased By ▼ -0.09 (-0.66%)
ASL 22.20 Decreased By ▼ -0.80 (-3.48%)
BOP 8.18 Decreased By ▼ -0.02 (-0.24%)
BYCO 7.55 Decreased By ▼ -0.26 (-3.33%)
FCCL 17.45 Decreased By ▼ -0.35 (-1.97%)
FFBL 22.10 Decreased By ▼ -0.65 (-2.86%)
FFL 15.20 Decreased By ▼ -0.30 (-1.94%)
FNEL 7.40 Increased By ▲ 0.05 (0.68%)
GGGL 17.00 Decreased By ▼ -0.83 (-4.66%)
GGL 39.30 Decreased By ▼ -0.71 (-1.77%)
HUMNL 5.76 Decreased By ▼ -0.26 (-4.32%)
JSCL 18.00 Decreased By ▼ -0.30 (-1.64%)
KAPCO 35.95 Decreased By ▼ -0.40 (-1.1%)
KEL 3.29 Decreased By ▼ -0.11 (-3.24%)
MDTL 2.50 Decreased By ▼ -0.15 (-5.66%)
MLCF 34.24 Decreased By ▼ -0.86 (-2.45%)
NETSOL 119.85 Decreased By ▼ -9.55 (-7.38%)
PACE 4.94 Increased By ▲ 0.19 (4%)
PAEL 26.53 Decreased By ▼ -0.47 (-1.74%)
PIBTL 8.71 Decreased By ▼ -0.14 (-1.58%)
POWER 7.25 Decreased By ▼ -0.20 (-2.68%)
PRL 16.97 Decreased By ▼ -0.18 (-1.05%)
PTC 9.65 Decreased By ▼ -0.36 (-3.6%)
SILK 1.50 No Change ▼ 0.00 (0%)
SNGP 45.10 Increased By ▲ 0.10 (0.22%)
TELE 17.48 Decreased By ▼ -1.41 (-7.46%)
TRG 161.00 Decreased By ▼ -1.70 (-1.04%)
UNITY 31.80 Decreased By ▼ -1.15 (-3.49%)
WTL 2.85 Decreased By ▼ -0.09 (-3.06%)
BR100 4,718 Decreased By ▼ -14.65 (-0.31%)
BR30 22,320 Decreased By ▼ -482.1 (-2.11%)
KSE100 45,074 Decreased By ▼ -223.36 (-0.49%)
KSE30 17,742 Decreased By ▼ -68.18 (-0.38%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
27,524
4224hr
Pakistan Cases
1,236,888
2,06024hr
4.58% positivity
Sindh
454,510
Punjab
427,583
Balochistan
32,837
Islamabad
104,913
KPK
172,766
Business & Finance

Indian vaccine makers end spat, pledge 'smooth rollout' of COVID-19 shots

  • Both companies respect the great work being carried out by each other and put behind us the miscommunication and misunderstanding caused during the past week.
  • India's drugs regulator on Sunday approved for emergency use a vaccine developed by AstraZeneca and Oxford University.
05 Jan 2021

NEW DELHI/BENGALURU: Serum Institute of India (SII) and Bharat Biotech said on Tuesday they would end a public spat and focus on rolling out COVID-19 shots after executives of both Indian vaccine makers clashed over the approval of their rival shots.

"Both companies respect the great work being carried out by each other and put behind us the miscommunication and misunderstanding caused during the past week," SII's Chief Executive Officer Adar Poonawalla and Bharat Biotech's Chairman Krishna Ella said in a joint statement.

India's drugs regulator on Sunday approved for emergency use a vaccine developed by AstraZeneca and Oxford University, which will be manufactured by SII, and another developed domestically by Bharat Biotech.

But the approval for Bharat Biotech's COVAXIN, developed with a government research body, faced criticism from industry experts and others as the company has yet to release efficacy and safety data, and it still has a Phase III trial underway.

"Until we get the efficacy result, how do we know that anything works?" Poonawalla told Reuters on Sunday.

Ella, however, defended both his firm and the approval for the vaccine in an online press conference on Monday.

"I want to say that it hurts as scientists. We work 24 hours. Do we deserve that type of bashing from the people?" Ella said, adding his firm was being picked on because it was Indian.

Ella also took a swipe at AstraZeneca, which said in November a dosing error had led to promising results in a subset of its trial volunteers.

In Tuesday's joint statement, the companies said they were fully aware of the importance of vaccines for people and countries and they jointly pledged to provide global access to their COVID-19 vaccines.

Comments

Comments are closed.